MannKind Corporation (NASDAQ:MNKD) VP David Thomson sold 30,000 shares of the stock on the open market in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $10.51, for a total transaction of $315,300.00. Following the transaction, the vice president now directly owns 102,286 shares in the company, valued at approximately $1,075,026. MannKind Corporation (NASDAQ:MNKD) stock performance was 9.60% in last session and finished the day at $10.96. Traded volume was 48.80million shares in the last session and the average volume of the stock remained 12.20million shares. The beta of the stock remained 1.19. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.30%.

Pfizer Inc. (NYSE:PFE) made an abortive $118 billion bid for AstraZeneca Plc, Valeant Pharmaceuticals International Inc is trying to buy Botox maker Allergan Inc for more than $50 billion, and AbbVie Inc plans to appeal to Shire Plc’s shareholders after an unsolicited $46 billion bid was rebuffed. Pfizer Inc. (NYSE:PFE) rose 0.03 percent to $29.68 Monday on volume of 20.57million shares. The intra-day range of the stock was $29.62 to $29.84. Pfizer Inc. (NYSE:PFE) has a market capitalization of $189.13billion.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) extends gains to hit a 17-month high after the biopharmaceutical company said the 18-month primary treatment period in the second phase 3 study of its Migalstat monotherapy for Fabry patients is now complete and top-line data are expected in Q3.  Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s stock on June 30, 2014 reported a increase of 10.23% to the closing price of $3.34. Its fifty two weeks range is $1.76 -$4.06. The total market capitalization recorded $214.90million. The overall volume in the last trading session was 18.55million shares. In its share capital, FOLD has 64.36million outstanding shares.

Geron Corporation (NASDAQ:GERN) on June 12 announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST). On Monday, shares of Geron Corporation (NASDAQ:GERN) advanced 8.08% to close the day at $3.21. Company return on investment (ROI) is -65.01% and its monthly performance is recorded as 54.33%. Geron Corporation (NASDAQ:GERN) quarterly revenue growth is 53.59%.

Gilead Sciences, Inc. (NASDAQ:GILD) is currently the market leader in Hepatits C treatment, and is on its way to make a fortune selling its breakthrough drug Sovaldi. The drug’s sales for 2014 may amount to anywhere between $7 billion to $12 billion, according to ISI Group. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -0.04% in last session and finished the day at $82.91. Traded volume was 10.89million shares in the last session and the average volume of the stock remained 15.01million shares. The beta of the stock remained 0.70. Gilead Sciences, Inc. (NASDAQ:GILD) insider ownership is 0.50%.